In fact, HCA said in its notice, in many cases, the discounts available [through Lilly and Novos programs] make the medications less expensive than what group health plans can negotiate with the manufacturers at this time. This article is exclusive to STAT+ subscribers Unlock this article plus in-depth analysis, newsletters, premium events, and news alerts
Chihara, K., et al (2006)
The battle over America's booming weight-loss drug market has a significant update, with a move thats likely to cause a shift across the healthcare and corporate benefits landscape: Cigna, one of Americas biggest insurers, is dropping coverage for GLP-1 obesity drugs, even for its own staff
Open Retatrutide Calculator Realistic Retatrutide FDA Timeline: 2027 to 2028 A defensible projected timeline has four moving pieces: Phase 3 completion, the NDA submission, the FDA review period, and the commercial launch ramp
Of these, BMI, waist circumference and weight loss of at least 15% were considered to have high quality levels ( Tables S32, 33 )